» Articles » PMID: 31882562

A Novel Model of Diabetic Complications: Adipocyte Mitochondrial Dysfunction Triggers Massive β-Cell Hyperplasia

Overview
Journal Diabetes
Specialty Endocrinology
Date 2019 Dec 29
PMID 31882562
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity-associated type 2 diabetes mellitus (T2DM) entails insulin resistance and loss of β-cell mass. Adipose tissue mitochondrial dysfunction is emerging as a key component in the etiology of T2DM. Identifying approaches to preserve mitochondrial function, adipose tissue integrity, and β-cell mass during obesity is a major challenge. Mitochondrial ferritin (FtMT) is a mitochondrial matrix protein that chelates iron. We sought to determine whether perturbation of adipocyte mitochondria influences energy metabolism during obesity. We used an adipocyte-specific doxycycline-inducible mouse model of FtMT overexpression (FtMT-Adip mice). During a dietary challenge, FtMT-Adip mice are leaner but exhibit glucose intolerance, low adiponectin levels, increased reactive oxygen species damage, and elevated GDF15 and FGF21 levels, indicating metabolically dysfunctional fat. Paradoxically, despite harboring highly dysfunctional fat, transgenic mice display massive β-cell hyperplasia, reflecting a beneficial mitochondria-induced fat-to-pancreas interorgan signaling axis. This identifies the unique and critical impact that adipocyte mitochondrial dysfunction has on increasing β-cell mass during obesity-related insulin resistance.

Citing Articles

The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice.

Yu X, Chen S, Funcke J, Straub L, Pirro V, Emont M Cell Metab. 2024; 37(1):187-204.e7.

PMID: 39642881 PMC: 11711001. DOI: 10.1016/j.cmet.2024.11.003.


Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.

Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F Signal Transduct Target Ther. 2024; 9(1):271.

PMID: 39396974 PMC: 11486532. DOI: 10.1038/s41392-024-01969-z.


The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review.

Negroiu C, Tudorascu R, Bezna M, Ungureanu A, Hontaru S, Danoiu S Rom J Morphol Embryol. 2024; 65(2):159-172.

PMID: 39020530 PMC: 11384831. DOI: 10.47162/RJME.65.2.02.


PAQR4 regulates adipocyte function and systemic metabolic health by mediating ceramide levels.

Zhu Q, Chen S, Funcke J, Straub L, Lin Q, Zhao S Nat Metab. 2024; 6(7):1347-1366.

PMID: 38961186 PMC: 11891014. DOI: 10.1038/s42255-024-01078-9.


Type 2 diabetic mellitus related osteoporosis: focusing on ferroptosis.

Chen Y, Zhao W, Hu A, Lin S, Chen P, Yang B J Transl Med. 2024; 22(1):409.

PMID: 38693581 PMC: 11064363. DOI: 10.1186/s12967-024-05191-x.


References
1.
Verdeguer F, Soustek M, Hatting M, Blattler S, McDonald D, Barrow J . Brown Adipose YY1 Deficiency Activates Expression of Secreted Proteins Linked to Energy Expenditure and Prevents Diet-Induced Obesity. Mol Cell Biol. 2015; 36(1):184-96. PMC: 4702598. DOI: 10.1128/MCB.00722-15. View

2.
Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M . Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int. 2016; 16 Suppl 1:17-29. DOI: 10.1111/ggi.12724. View

3.
Gomez-Samano M, Grajales-Gomez M, Zuarth-Vazquez J, Navarro-Flores M, Martinez-Saavedra M, Juarez-Leon O . Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017; 11:335-341. PMC: 5200873. DOI: 10.1016/j.redox.2016.12.024. View

4.
Kang S, Han J, Song S, Kim W, Shin S, Kim J . Lysophosphatidic acid increases the proliferation and migration of adipose‑derived stem cells via the generation of reactive oxygen species. Mol Med Rep. 2015; 12(4):5203-10. DOI: 10.3892/mmr.2015.4023. View

5.
Kempf T, Guba-Quint A, Torgerson J, Magnone M, Haefliger C, Bobadilla M . Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol. 2012; 167(5):671-8. DOI: 10.1530/EJE-12-0466. View